Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Inicie sesión o únase ahora para utilizar esta función

Recruiting

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function - MB130-065

Actualizada: 01 November, 2018   |   ClinicalTrials.gov

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.

Detalles del estudio

  • Phase 1

    Fase

  • Géneros

  • 21-75

    Rango de edad

  • Recruiting

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Experimental: Mild Renal Impairment
Drug: BMS-986036
Experimental: Moderate Renal Impairment
Drug: BMS-986036
Other: Normal
Drug: BMS-986036
Experimental: Severe Renal Impairment
Drug: BMS-986036

Criterios clave de elegibilidad

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - BMI ≥ 25 and ≤ 40 kg/m2 Exclusion Criteria: - Presence of any factors that would predispose the participant to infection (eg, extensive periodontal disease that warrants surgical or medical treatment, unhealed open wounds) - Any bone trauma (fracture) or bone surgery (ie, hardware placement, joint replacement, bone grafting, or amputation) within 3 months of study drug administration - Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status - Any major surgery (eg, abdominal, thoracal, or cranial procedures) within 6 weeks of study drug administration - Donation of blood or plasma to a blood bank, or in a clinical study (except at the screening visit) within 6 weeks of study drug administration - Inability to tolerate subcutaneous injections Other protocol defined inclusion/exclusion criteria could apply

¿Tiene alguna pregunta? Llame 855-907-3286 o Envíenos un correo electrónico

¿Tiene alguna pregunta?
Llame 855-907-3286 o Envíenos un correo electrónico